Brand & Intangible Asset Valuation

Intangible assets — brands, patents, customer contracts, non-compete agreements, technology platforms — often constitute the majority of enterprise value in services, pharma, and technology businesses, yet they remain off the balance sheet unless acquired. Our intangible asset valuation covers: brand valuation using relief-from-royalty or multi-period excess earnings method; patent and IP valuation; purchase price allocation (PPA) for M&A transactions (Ind AS 103); impairment testing under Ind AS 36; and royalty rate benchmarking for transfer pricing. Deliverables meet Ind AS, ICAI valuation standards, and SEBI registered valuer requirements.